Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes

In most follow-up samples, MRD estimates by two methods are in agreement, especially in patients with TCF3-PBX1.